continua IL black FRIDAY al CUBO |15% su tutto con il coupon 15alcubo | SCOPRI di più

Customer care
  • Lasonil Pain Relief 10% Bayer Anti-inflammatory Gel 50g -37%

Lasonil Pain Relief 10% Bayer Anti-inflammatory Gel 50g

5.58€ 8.80€
  • Brand: BAYER SpA
  • Product Code: 042154017
  • EAN:
  • Availability: In Stock
  • Purchase 3 items for 5.47€ each
  • Purchase 4 items for 5.36€ each
  • Purchase 5 items for 5.25€ each

Lasonil Pain Relief 10% Bayer Anti-inflammatory Gel

The 10% Lasonil Anti Pain Gel is used in the local treatment of bruises, sprains, myalgias, muscle tears, stiff neck, it is the ideal partner when situations arise that can cause joint and muscle pain.

This product is very useful both for athletes who can use it in the event of an injury and for problems related to injuries caused in everyday life, also excellent for those suffering from back problems.

Composition

Lasonil Pain Relief Gel 10% contains:
Active ingredient: Ibuprofen lysine salt 10 g
Excipients: Sodium para-oxybenzoate of methyl, sodium para-oxybenzate of ethyl.

Dosage and method of use

The application of the product is very simple, 2-4 applications per day are recommended on the painful part, for elderly patients they should follow the minimum dosages indicated above, just apply a thin layer of gel on the part to be treated with a light circular massage until by absorption, use the medicine for the shortest period possible, wash hands thoroughly and prolonged after application.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients.
  • Due to the possibility of cross-sensitization, the medicinal product should not be administered to patients in whom acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations.
  • Pregnancy.
  • Feeding time
  • Children and adolescents under the age of 14.

Special warning

The application of Lasonil Pain Relief should be avoided at open wounds or skin lesions. The use of Lasonil Pain Relief, like any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended for women who intend to become pregnant. Lasonil Pain Relief should be discontinued in women who have fertility problems or who are undergoing fertility investigations. The use of Lasonil Antidolore, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity stop treatment and take appropriate therapeutic measures.

To avoid more severe hypersensitivity or photosensitization phenomena, the patient should not expose himself to direct sunlight, including the solarium, during treatment and for the following two weeks. In the event of allergic reactions or major adverse reactions (skin reactions, some of them fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) it is necessary to immediately discontinue therapy. Patients appear to be at higher risk in the early stages of therapy: the onset of skin reactions occur in most cases within the first month of treatment. Do not use Lasonil Pain Relief together with another NSAID or, in any case, do not use more than one NSAID at a time.

Pregnancy and breastfeeding

The use of Lasonil Pain Relief is contraindicated in pregnancy and breastfeeding. Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to about 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre and post implantation loss and embryo / fetal mortality. In addition, an increase in the incidence of various malformations, including cardiovascular malformations, has been reported in animals that have been given prostaglandin synthesis inhibitors during the genetic organ period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may exhibit:

  • the fetus with cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension), renal dysfunction, which can progress to renal failure with oligo-hydroamnios;
  • the mother and the newborn, at the end of pregnancy, a possible prolongation of the bleeding time, and antiplatelet effect that can occur even at very low doses and inhibition of uterine contractions resulting in delayed or prolonged labor.

Expiration and Conservation

It is important to see the expiry date shown on the package, nNot particular attention is required for the storage of the product, the important thing is to keep the product out of the reach of children, keep it in a dry place away from sources of heat and humidity, it is important the expiry date refers to the product in intact packaging, it is important not to use the medicine after the expiry date indicated on the package.

Format

The product is sold in a 50g tube ready for use.

.